A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

October 14, 2026

Study Completion Date

October 14, 2026

Conditions
Alzheimer's Disease
Interventions
DRUG

RO7269162

Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.

DRUG

Placebo

Participants will receive daily doses of placebo for up to 72 weeks.

Trial Locations (50)

2100

Rigshospitalet, Hukommelsesklinikken, Koebenhavn Oe

8195

Hospital General De Catalunya, Sant Cugat del Vallès

8200

Aarhus Universitetshospital Skejby, Aarhus N

12200

Ambulates Gesundheitszentrum der Charité GmbH, Berlin

13125

ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic, Berlin

13385

Hôpital de la Timone, Marseille

14004

Hospital Universitario Reina Sofia, Córdoba

20014

Policlínica Guipuzcoa, Donostia / San Sebastian

20132

IRCCS Ospedale San Raffaele, Milan

21565

Gachon University Gil Medical Center, Incheon

22332

Inha University Hospital, Incheon

27100

Fondazione Istituto Neurologico Mondino IRCCS, Pavia

28041

Hospital Universitario 12 de Octubre, Madrid

28223

Hospital Quiron de Madrid, Pozuelo de Alarcón

31059

Gerontopole, Toulouse

37007

Complejo Asistencial Universitario de Salamanca, Salamaca

41009

Hospital Victoria Eugenia, Seville

41013

Hospital Virgen del Rocío, Seville

44800

Hop Guillaume Et Rene Laennec, Saint-Herblain

46017

Hospital Universitario Dr. Peset, Valencia

46026

Hospital Universitario la Fe, Valencia

59037

Hopital B Roger Salengro, Lille

67000

Hôpital Robertsau, Strasbourg

69677

Groupement Hospitalier Est - Hôpital Neurologique, Bron

73039

Ospedale Cardinale Panico, Tricase (LE)

75010

Hôpital Lariboisière, Paris

76031

CHU de Rouen Hopital, Rouen

81675

Klinikum rechts der Isar der TU München, München

8330034

Centro de Investigación Clínica UC-CICUC, Santiago

Unknown

Hospital Clinico Univ de Chile, Santiago

00185

Umberto I Policlinico di Roma-Università di Roma La Sapienza, Rome

06156

AO di Perugia - Ospedale S. Maria della Misericordia, Perugia

44-240

ProNeuro Centrum Medyczne, ?ory

15-756

Podlaskie Centrum Psychogeriatrii, Bia?ystok

85-079

NZOZ Vitamed, Bydgoszcz

40-749

NEURO-CARE Sp. z o.o. Sp. Komandytowa, Katowice

30-688

Szpital Uniwersytecki w Krakowie, Krakow

81-855

Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot

70-111

EUROMEDIS Sp z o o, Szczecin

02-777

ETG Neuroscience Sp. z o.o., Warsaw

53-659

NZOZ WCA, Wroc?aw

08028

Fundacio ACE, Barcelona

B16 8QQ

Re:Cognition Health Birmingham, Birmingham

KT16 9AU

Surrey and Borders NHS Foundation Trust, Chertsey

EH12 9DQ

Scottish Brain Sciences, Edinburgh

W1G 8TA

RE:Cognition Health, London

W6 8RF

Charing Cross Hospital, London

M13 9WL

Manchester Mental Health and Social Care Trust, Manchester

NE4 5PL

Campus for Ageing & Vitality, Newcastle

SO16 6YD

Southampton General Hospital, Southampton

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06402838 - A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | Biotech Hunter | Biotech Hunter